Cell-based potency assays are lab tests that use living cells to measure whether a biological drug actually does what it’s supposed to do. Unlike simple chemical tests that check if a molecule is present, these assays measure functional biological activity: can this drug trigger the right cellular response at the right strength? They are a core requirement for manufacturing and releasing biologic therapies, including monoclonal antibodies, cell therapies, and gene therapies.
Why Potency Testing Requires Living Cells
Biologic drugs are far more complex than traditional small-molecule pills. A monoclonal antibody, for example, is a large protein whose therapeutic effect depends on its three-dimensional shape, how it folds, and how it interacts with receptors on human cells. You can’t confirm all of that with a simple chemical measurement. You need to see the drug act on cells and produce a measurable biological response.
The FDA defines potency as “the specific ability or capacity of the product to effect a given result,” and federal regulations require that potency tests be specifically designed for each product to indicate its biological activity. In practical terms, this means that for most biologics, a cell-based assay is the gold standard because it mirrors what the drug will actually do inside the body. Surrogate measurements like binding strength or protein expression can supplement potency data, but they don’t directly measure function the way a cell-based assay does.
How These Assays Work
The basic concept is straightforward: expose a carefully chosen cell line to the drug, then measure what happens. The specific readout depends on the drug’s mechanism of action. There are several common formats.
Proliferation and inhibition assays measure whether a drug causes target cells to grow or stop growing. A growth factor intended to stimulate immune cells, for instance, would be tested by adding it to immune cells and counting how many divide. Conversely, a drug meant to suppress tumor cell growth would be tested by measuring how effectively it slows proliferation. These assays require cells that express the right receptors for the drug being tested.
Reporter gene assays use engineered cell lines that light up when the drug activates a specific signaling pathway. The cells are modified to produce a glowing protein (luciferase) whenever a particular molecular switch is flipped inside them. For drugs that activate immune cells, the engineered cells might produce luciferase in response to T-cell activation pathways. The brighter the glow, the more potent the drug. These assays have become popular for quality control because they’re more consistent and easier to standardize than assays that rely on cell killing.
Cytotoxicity assays measure a drug’s ability to kill target cells. This is particularly relevant for cancer-targeting antibodies, where the therapeutic effect depends on recruiting immune cells to destroy tumor cells or activating the body’s complement system to punch holes in them. The readout is typically the percentage of target cells killed at a given drug concentration.
Measuring Relative Potency
Potency assays don’t just produce a pass/fail result. They generate dose-response curves: as you increase the drug concentration, the cellular response increases in a predictable pattern. The test sample’s curve is compared against a well-characterized reference standard of the same product. The result is expressed as relative potency, typically a percentage where 100% means the test batch matches the reference exactly.
This comparison uses mathematical models to fit the dose-response data. The curves from the test sample and reference must be parallel, meaning the drug behaves in the same fundamental way, just stronger or weaker. If the curves aren’t parallel, the comparison isn’t valid, which itself can signal a quality problem with the batch. Regulatory guidelines recommend testing at least five concentration levels across the assay’s working range to establish that results are reliable.
Where Potency Assays Fit in a Drug’s Lifecycle
Potency testing isn’t a one-time checkpoint. It follows a biologic product through its entire lifecycle. During development, potency assays help characterize the product and establish what “normal” biological activity looks like. Once manufacturing begins, every batch must pass a potency test before it can be released for patient use. This is a legal requirement under FDA regulations for all licensed biological products.
Potency assays also play a central role in stability testing. Biologic drugs can degrade over time, and a product that looks chemically intact might have lost its ability to function. Running potency assays on stored samples at regular intervals reveals whether the drug maintains its activity throughout its shelf life. A decline in potency over time tells manufacturers that storage conditions or formulation need adjustment.
For cell and gene therapies, the FDA recommends what it calls a “potency assurance strategy,” a layered approach that combines manufacturing process controls, in-process testing, and final potency release assays. This reflects the reality that living-cell products are inherently variable and that no single test captures every dimension of quality.
Managing Variability
The biggest challenge with cell-based potency assays is that living cells introduce biological variability. Cells can behave differently depending on how many times they’ve been divided (passage number), how they were stored, what batch of growth serum fed them, and even the temperature during a single step of the protocol. This variability can obscure the true potency signal.
Careful protocol control makes an enormous difference. In one published example, researchers decomposed the total variability of a cell-based bioassay into its component sources and found that variation between individual sample preparations accounted for most of the noise. By identifying and tightly controlling just five key protocol parameters, with activation temperature being the single most impactful factor, they reduced total assay variability by roughly 85%.
Other standard practices include banking large quantities of cells at a defined passage number so every test uses functionally identical cells, qualifying each new lot of serum or reagent before use, and running the reference standard on every plate to normalize results. Reporter gene assays have gained favor partly because engineered cell lines tend to be more uniform and stable than primary cells, which reduces run-to-run variation.
Validation Requirements
Before a potency assay can be used for batch release, it must be formally validated to prove it produces accurate, reproducible, and meaningful results. International guidelines from the ICH lay out the framework. For potency assays specifically, validation covers several key parameters.
- Accuracy: The assay must recover the known potency of spiked or diluted samples at multiple levels, typically at least five, across its reportable range.
- Precision: Results must be consistent when repeated by different analysts, on different days, and with different equipment. This “intermediate precision” testing captures the real-world variation a lab will face.
- Reportable range: The assay must perform reliably from the lowest to highest relative potency values it’s expected to measure. Guidelines suggest this range should extend at least 20% beyond the specification acceptance limits in both directions.
These validation studies are extensive and can take months. For early-phase clinical trials, regulators accept less-developed assays, but by the time a product is licensed, the potency assay must be fully validated and locked down. Any change to the assay protocol after that point requires formal change control and often revalidation.